Key statistics
As of last trade, Aurinia Pharmaceuticals Inc (IKAP:DUS) traded at 6.42, 45.85% above the 52 week low of 4.40 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.42 |
---|---|
High | 6.42 |
Low | 6.42 |
Bid | 6.42 |
Offer | 6.56 |
Previous close | 6.39 |
Average volume | 0.00 |
---|---|
Shares outstanding | 142.99m |
Free float | 132.88m |
P/E (TTM) | -- |
Market cap | 1.02bn USD |
EPS (TTM) | -0.3508 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 07:10 BST.
More ▼
Press releases
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
- Aurinia Announces Board Restructuring
- Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
- Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
- Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board
- venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
- ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders’ Voices Expressed at the AGM
More ▼